Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03860883 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Study acronym: MelMarT-II
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 71 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 3 to Not applicable Study sites: 148 to 192 · Eligibility criteria expanded, about 80 words · Secondary endpoints revised (10)v71 Show 3 more changesShow less
    • Study sites: 148 to 192
    • Eligibility criteria expanded, about 80 words
    • Secondary endpoints revised (10)

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 145 to 148v70
  3. Study sites: 144 to 145v69
  4. Study sites: 143 to 144v68
  5. Study sites: 138 to 143v67
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 126 to 138v66
  2. Study sites: 120 to 126v65
  3. Study sites: 117 to 120v64
  4. Study sites: 105 to 117v63
  5. Study sites: 97 to 105v62
  6. Study sites: 96 to 97v61
  7. Study sites: 94 to 96v60
  8. Study sites: 84 to 94v59
  9. Study sites: 78 to 84v58
  10. Study sites: 73 to 78v57
  11. Study sites: 58 to 73v56
  12. Study sites: 46 to 58v55
  13. Study sites: 45 to 46v54
  14. Study sites: 41 to 45v53
  15. Study sites: 39 to 41v52
  16. Eligibility criteria expanded, about 82 wordsv51 See this version in full on ClinicalTrials.gov ↗
  17. Site contacts updated at 1 of 39 sitesv50
  18. Study sites: 38 to 39v49
  19. Study sites: 37 to 38v48
  20. Study sites: 36 to 37v47
  21. Site details revised at 1 of 36 sitesv46
  22. Site details revised at 1 of 36 sitesv45
  23. Study sites: 35 to 36v44
  24. Study sites: 34 to 35v43
  25. Site details revised at 1 of 34 sitesv42
  26. Site details revised at 1 of 34 sitesv41
  27. Study sites: 33 to 34 Collaborators: 2 to 4v40 Show 1 more changeShow less
    • Collaborators: 2 to 4

    See this version in full on ClinicalTrials.gov ↗

  28. Study sites: 32 to 33v39
  29. Site details revised at 1 of 32 sitesv38
  30. Study sites: 31 to 32v37
  31. Study sites: 30 to 31v36
  32. Study sites revised (30)v35 See this version in full on ClinicalTrials.gov ↗
  33. Site details revised at 1 of 30 sitesv34
  34. Site details revised at 1 of 30 sitesv33
  35. Study sites: 29 to 30v32
  36. Site details revised at 1 of 29 sitesv31
  37. Eligibility criteria expanded, about 93 words Secondary endpoints: details revised at 1 of 10 entriesv30 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 10 entries

    See this version in full on ClinicalTrials.gov ↗

  38. Re-verified, no change to tracked fieldsv29
  39. Site details revised at 1 of 29 sitesv28
  40. Study sites: 28 to 29v27
  41. Study sites: 27 to 28v26
  42. Site details revised at 1 of 27 sitesv25
  43. Site details revised at 1 of 27 sitesv24
  44. Site details revised at 1 of 27 sitesv23
  45. Study sites: 26 to 27v22
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Trial Details
NCT Number NCT03860883
Lead Sponsor Melanoma and Skin Cancer Trials Limited
Collaborators: Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Conditions Cutaneous Melanoma, Stage II
Enrollment 2,998 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov